Notably, a combination of immunotherapy using the vaccine and anti-CTLA-4 monoclonal antibody was found to significantly enhance anti-tumor immune response, relative to mRNA or monoclonal antibody therapies alone (108). Here, CTLA4 is linked to neoplasm.